Cargando…
Rapid de-localization of actin leading edge components with BDM treatment
BACKGROUND: 2,3-Butanedione monoxime (BDM) has been widely used as a non-muscle myosin inhibitor to investigate the role of non-muscle myosinII in the process of actin retrograde flow and other actin cytoskeletal processes. Recent reports show that BDM does not inhibit any non-muscle myosins so far...
Autores principales: | Yarrow, Justin C, Lechler, Terry, Li, Rong, Mitchison, Timothy J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165424/ https://www.ncbi.nlm.nih.gov/pubmed/12783627 http://dx.doi.org/10.1186/1471-2121-4-5 |
Ejemplares similares
-
Electronique pour BDM (Beam Dimensions Monitor)
por: Battisti, S, et al.
Publicado: (1968) -
Dataset and protocols on the applicability of the BDM mechanism in product evaluation
por: Lichters, Marcel, et al.
Publicado: (2019) -
Variety in leading edge actin
por: LeBrasseur, Nicole
Publicado: (2008) -
Industry news: 2020 high-impact publications in the BDM area
por: Ma, Liang
Publicado: (2021) -
In Vitro Reconstitution of Cortical Actin Assembly Sites in Budding Yeast
por: Lechler, Terry, et al.
Publicado: (1997)